Compare · FBRX vs NVO
FBRX vs NVO
Side-by-side comparison of Forte Biosciences Inc. (FBRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FBRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 222.7x FBRX ($1.00B).
- Over the past year, FBRX is up 368.6% and NVO is down 22.5% - FBRX leads by 391.1 points.
- FBRX has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 12 for FBRX).
- Company
- Forte Biosciences Inc.
- Novo Nordisk A/S
- Price
- $48.92+8.45%
- $50.31-2.25%
- Market cap
- $1.00B
- $222.81B
- 1M return
- +185.08%
- +15.47%
- 1Y return
- +368.58%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 6
- 4
- Recent ratings
- 12
- 25
Forte Biosciences Inc.
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FBRX
- Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.
- Forte Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
- Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.
- CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.57% to 42,600 units (SEC Form 4)
- Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 85,482 units (SEC Form 4)
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Riley Antony A
- SEC Form 4 filed by Officer Wagner Paul A.
- SEC Form EFFECT filed by Forte Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Forte Biosciences Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S